Sanofi (XSWX:SAN) Moat Score: 8/10 (As of Jun. 27, 2026)


XSWX:SAN Sanofi SA XSWX:SAN
87 GF Score
Price CHF73.20
GF Value CHF104.30
! 2 Warning Signs
View Full Analysis

What is Sanofi Moat Score?

Sanofi XSWX:SAN 87 Moat Score is 8 as of Jun. 27, 2026. GuruFocus rates XSWX:SAN with a GF Score™ of 87/100 and a GF Value™ of CHF104.30. The stock has 2 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Sanofi ranks better than 99.71% on this metric.

Sanofi has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Sanofi has Wide Moat: Sanofi SA has a robust wide moat due to its strong brand, valuable patents, and significant regulatory barriers in the pharmaceutical industry. It possesses durable cost advantages and consistent innovation capabilities, ensuring a dominant market position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sanofi might have Wide Moat - Clear and robust wide moat.

Sanofi  (XSWX:SAN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sanofi Moat Score Related Terms

XSWX:SAN vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Moat Score distribution charts can be found below:

* The bar in red indicates where Sanofi's Moat Score falls into.


XSWX:SAN
87GF Score
Sanofi SA XSWX:SAN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Sanofi (XSWX:SAN) has a Moat Score of 8 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sanofi ranks #3 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Sanofi's Moat Score too high?
Sanofi's current Moat Score is 8. Based on the distribution chart, Sanofi ranks #3 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #3 out of 1033 companies for Moat Score. This places Sanofi in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sanofi's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Moat Score of 8. The stock's GF Value™ is CHF104.30, compared to a current price of CHF73.20 — trading 29.8% below its estimated fair value. The current Moat Score is 8. Sanofi's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Moat Score is 8 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.8% below its estimated GF Value™ of CHF104.30.

Key valuation signals for XSWX:SAN:

  • Moat Score: 8
  • GF Value™: CHF104.30 vs. price of CHF73.20 (29.8% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
87GF Score

Get the complete analysis for XSWX:SAN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF104.30
GF Value